The global pharmaceutical stability and storage services market size, valued at USD 3.53 billion in 2024, is projected to reach USD 7.97 billion by 2034, according to a report by Zion Market Research.

The market is estimated to grow annually at a CAGR of around 8.50 percent between 2025 and 2034.  

The report identified factors driving the growth, including the rising demand for high-quality drug development processes, stringent regulatory compliance, and increasing outsourcing of stability testing and storage solutions by pharmaceutical and biotechnology companies.    

Pharmaceutical stability and storage services play a vital role in determining the shelf life, efficacy, and safety of drugs under various environmental conditions, including temperature, humidity, and light. These services are essential across the pharmaceutical value chain— from early-stage development to commercial production.

North America is set to remain the largest market, fuelled by advanced R&D infrastructure, strong regulatory frameworks, and significant investments in biologics and gene therapy. The US continues to lead with significant demand for outsourced stability testing and long-term storage solutions.

APAC is expected to register the fastest CAGR during the forecast period, supported by cost-effective outsourcing opportunities, expanding pharmaceutical manufacturing, and increasing clinical trial activities in India, China, South Korea, and Singapore.  

Europe holds a substantial share, driven by stringent EMA guidelines, a growing biosimilars market, and strong presence of global contract research organisations. Germany, the UK, and Switzerland are key markets in the region.

Latin America, particularly Brazil and Mexico, is experiencing steady demand growth due to strengthening healthcare infrastructure and expanding drug production capabilities.

Middle East and Africa (MEA), though smaller in size, is expanding with increased government healthcare investments and international collaborations in pharmaceutical research and vaccine distribution.

Based on service type, accelerated stability testing currently leads the market and is expected to maintain its dominance throughout the forecast period. In terms of application, regulatory compliance is projected to remain the primary driver of demand. By distribution channel, contract research organisations (CROs) are anticipated to hold the largest market share, while among end-users, large pharmaceutical companies are expected to continue leading the market.

Major key players include Charles River Laboratories, Eurofins Scientific, Intertek Group plc, SGS SA, Pace Analytical Services LLC, Almac Group, WuXi AppTec, Cambrex Corporation, Catalent, and PCI Pharma Services.

“These players are focusing on global facility expansion, AI-driven stability monitoring, and advanced cold-chain logistics to strengthen market presence,” the report noted.

Looking forward, the rising complexity of biologics, the expansion of cell and gene therapy pipelines, and increasing demand for personalised medicine are expected to intensify the need for advanced stability testing and specialised storage conditions.

Emerging trends shaping the next decade include: Digitalisation of stability data using AI and cloud-based platforms; blockchain-based supply chain tracking for improved transparency; expansion of ultra-low temperature facilities to support next-generation therapies; and strategic partnerships between CROs and pharma companies to enhance service offerings.

“By 2034, the market will be defined by technology-driven, globalised, and highly specialised services, ensuring that new therapies remain safe, effective, and compliant with international standards,” the report added.